Lets be transparent (show source data) and not just show one side of the story. Also, lets provide a time frame for context. This will make it CLEAR so ppl can make the correct comparison with ADMP and Tempol.
"In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[4] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.[5] "
Also, the links I previously provided showed progression and use of drug in patients, not animals as in story above, plus were done after the whistle blower complaint. The conclusions of the human study are shown below with source data in links under it.
"Conclusions
Molnupiravir is the first oral, direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile."
News 
Market Data 
Discover 
